Cargando…

Ganetespib radiosensitization for liver cancer therapy

Therapies for liver cancer particularly those including radiation are still inadequate. Inhibiting the stress response machinery is an appealing anti-cancer and radiosensitizing therapeutic strategy. Heat-shock-protein-90 (HSP90) is a molecular chaperone that is a prominent effector of the stress re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chettiar, Sivarajan T., Malek, Reem, Annadanam, Anvesh, Nugent, Katriana M., Kato, Yoshinori, Wang, Hailun, Cades, Jessica A., Taparra, Kekoa, Belcaid, Zineb, Ballew, Matthew, Manmiller, Sarah, Proia, David, Lim, Michael, Anders, Robert A., Herman, Joseph M., Tran, Phuoc T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4910914/ https://www.ncbi.nlm.nih.gov/pubmed/26980196 http://dx.doi.org/10.1080/15384047.2016.1156258

Ejemplares similares

Structure-Function Studies of the bHLH Phosphorylation Domain of TWIST1 in Prostate Cancer Cells()()
por: Gajula, Rajendra P., et al.
Publicado: (2015)

The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer
por: He, Suqin, et al.
Publicado: (2014)

The HSP90 Inhibitor Ganetespib Radiosensitizes Human Lung Adenocarcinoma Cells
por: Gomez-Casal, Roberto, et al.
Publicado: (2015)

Hijacking the Hexosamine Biosynthetic Pathway to Promote EMT-Mediated Neoplastic Phenotypes
por: Taparra, Kekoa, et al.
Publicado: (2016)

Concurrent versus Sequential Sorafenib Therapy in Combination with Radiation for Hepatocellular Carcinoma
por: Wild, Aaron T., et al.
Publicado: (2013)

Ganetespib: research and clinical development
por: Jhaveri, Komal, et al.
Publicado: (2015)

Native Hawaiian and Other Pacific Islander Representation Among US Allopathic Medical Schools, Residency Programs, and Faculty Physicians
por: Taparra, Kekoa, et al.
Publicado: (2021)

Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes
por: Friedland, Julie C., et al.
Publicado: (2013)

Disparities in Survival and Comorbidity Burden Between Asian and Native Hawaiian and Other Pacific Islander Patients With Cancer
por: Taparra, Kekoa, et al.
Publicado: (2022)

Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models
por: Proia, David A., et al.
Publicado: (2012)

The Game Continues: Seeking Clarity in the Radiation Oncology Match
por: Ebner, Daniel K., et al.
Publicado: (2020)

Multifaceted Intervention by the Hsp90 Inhibitor Ganetespib (STA-9090) in Cancer Cells with Activated JAK/STAT Signaling
por: Proia, David A., et al.
Publicado: (2011)

Descemet membrane endothelial keratoplasty in a patient with iris-fixated intraocular lens and prior radial keratotomy: a case report
por: Annadanam, Anvesh, et al.
Publicado: (2021)

UDP glucuronosyltransferase 1A expression levels determine the response of colorectal cancer cells to the heat shock protein 90 inhibitor ganetespib
por: Landmann, H, et al.
Publicado: (2014)

Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression
por: HE, SUQIN, et al.
Publicado: (2012)

Activity of the Heat Shock Protein 90 Inhibitor Ganetespib in Melanoma
por: Wu, Xinqi, et al.
Publicado: (2013)

The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer
por: Smith, Donald L., et al.
Publicado: (2014)

Definitive Treatment of Brain Metastases From a Neuroendocrine Tumor With Peptide Receptor Radionuclide Therapy With 177Lutetium DOTATATE: A Case Report
por: Zhang, Vivian, et al.
Publicado: (2023)

Efficacy of an HSP90 inhibitor, ganetespib, in preclinical thyroid cancer models
por: Lin, Shu-Fu, et al.
Publicado: (2017)

Targeting mitochondrial translation by inhibiting DDX3: a novel radiosensitization strategy for cancer treatment
por: Heerma van Voss, Marise R., et al.
Publicado: (2017)

The Impact of COVID-19 on Radiation Oncology Residency Applicant Away Rotations, Interviews, and Rank Lists: A Comparison Between the 2020 Match and 2021 Match
por: Taparra, Kekoa, et al.
Publicado: (2021)

Away Rotations, Interviews, and Rank Lists: Radiation Oncology Residency Applicant Perspectives on the 2020 Match Process
por: Taparra, Kekoa, et al.
Publicado: (2021)

HSP-90 Inhibitor Ganetespib is Synergistic with Doxorubicin in Small Cell Lung Cancer
por: Lai, Chien-Hao, et al.
Publicado: (2013)

Effects of Hsp90 Inhibitor Ganetespib on Inhibition of Azole-Resistant Candida albicans
por: Yuan, Rui, et al.
Publicado: (2021)

Cancer Disparities among Pacific Islanders: A Review of Sociocultural Determinants of Health in the Micronesian Region
por: Pineda, Eric, et al.
Publicado: (2023)

Targeting heat-shock protein 90 with ganetespib for molecularly targeted therapy of gastric cancer
por: Liu, H, et al.
Publicado: (2015)

A Phase I Study of Ganetespib and Ziv‐Aflibercept in Patients with Advanced Carcinomas and Sarcomas
por: Meehan, Robert, et al.
Publicado: (2018)

Corrigendum: Effects of Hsp90 Inhibitor Ganetespib on Inhibition of Azole-Resistant Candida albicans
por: Yuan, Rui, et al.
Publicado: (2021)

Racial Disparities among Asian American, Native Hawaiian, and Other Pacific Islander Patients with Cancer Who Refuse Recommended Radiation Therapy or Surgery
por: Lau, Brianna, et al.
Publicado: (2023)

Racial and Ethnic Disparities in Rates of Invasive Second Breast Cancer Among Women With Ductal Carcinoma In Situ in Hawaiʻi
por: Taparra, Kekoa, et al.
Publicado: (2021)

Recombination map tailored to Native Hawaiians improves robustness of genomic scans for positive selection
por: Dinh, Bryan L., et al.
Publicado: (2023)

Role of Ganetespib, an HSP90 Inhibitor, in Cancer Therapy: From Molecular Mechanisms to Clinical Practice
por: Youssef, Mahmoud E., et al.
Publicado: (2023)

The HSP90 inhibitor ganetespib: A potential effective agent for Acute Myeloid Leukemia in combination with cytarabine
por: Lazenby, M., et al.
Publicado: (2015)

Ganetespib selectively sensitizes cancer cells for proximal and distal spread-out Bragg peak proton irradiation
por: Deycmar, Simon, et al.
Publicado: (2022)

The HSP-RTK-Akt axis mediates acquired resistance to Ganetespib in HER2-positive breast cancer
por: Eyermann, Christopher E., et al.
Publicado: (2021)

Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer
por: Lang, Julie E., et al.
Publicado: (2022)

Evaluation of the Heat Shock Protein 90 Inhibitor Ganetespib as a Sensitizer to Hyperthermia-Based Cancer Treatments
por: Scutigliani, Enzo M., et al.
Publicado: (2022)

Nanomedicine-Assisted Combination Therapy of NSCLC: New Platinum-Based Anticancer Drug Synergizes the Therapeutic Efficacy of Ganetespib
por: Kallu, Jyothi, et al.
Publicado: (2019)

Ganetespib synergizes with cyclophosphamide to improve survival of mice with autochthonous tumors in a mutant p53-dependent manner
por: Alexandrova, Evguenia M, et al.
Publicado: (2017)

HSP90 Inhibitor Ganetespib Enhances the Sensitivity of Mantle Cell Lymphoma to Bruton’s Tyrosine Kinase Inhibitor Ibrutinib
por: Lu, Ziwen, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tr1bfrq6khbh5kua24r58lsv7v